Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.

Authors

Robin Jones

Robin Lewis Jones

Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom

Robin Lewis Jones , Jean-Yves Blay , Suzanne George , Hans Gelderblom , Patrick Schöffski , Margaret von Mehren , John Raymond Zalcberg , Yoon-Koo Kang , Albiruni Ryan Abdul Razak , Jonathan C. Trent , Steven Attia , Axel Le Cesne , William Reichmann , Haroun Achour , Matthew L. Sherman , Rodrigo Ruiz-Soto , Sebastian Bauer , Michael C. Heinrich

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Gastrointestinal Stromal Tumors (GIST)

Clinical Trial Registration Number

NCT03673501

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 11524)

DOI

10.1200/JCO.2023.41.16_suppl.11524

Abstract #

11524

Poster Bd #

458

Abstract Disclosures

Similar Posters

First Author: John Raymond Zalcberg

First Author: Jonathan C. Trent

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A retrospective analysis of the efficacy and safety of imatinib in elderly patients with advanced gastrointestinal stromal tumor.

A retrospective analysis of the efficacy and safety of imatinib in elderly patients with advanced gastrointestinal stromal tumor.

First Author: Takahito Awatsu